This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hospira Names Matthew R. Stober Senior Vice President Of Operations

LAKE FOREST, Ill., April 15, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced that Matthew R. (Matt) Stober has been named senior vice president, Operations, effective today. In addition to expanding his current U.S. responsibilities to assume leadership for all of Hospira's pharmaceutical manufacturing operations, Mr. Stober will have responsibility for the operations functions, including manufacturing science and technology, engineering, competitive strategy, health and safety, supply chain and procurement. Mr. Stober succeeds John B. Elliot, who has led the Operations organization since April 2012 and will provide continuity of support until his retirement at the end of the year. Both Mr. Elliot and Mr. Stober will serve as members of the company's senior leadership team, led by F. Michael Ball, chief executive officer.

"Matt brings the perfect blend of vision and experience to our operations organization, backed by a proven track record of success at Hospira," said Mr. Ball. "In his expanded role, we're confident Matt will continue to successfully advance our dual commitment to remediate and modernize our processes and operations while delivering patient-critical products, and ultimately establish our manufacturing operations as a strategic, competitive advantage. We thank John for his strong counsel and continued support during the transition and look forward to Matt's many additional contributions."  

Mr. Stober, 45, joined Hospira in 2011 as its corporate vice president, U.S. Pharma Operations, where he has held primary responsibility for Hospira's Rocky Mount, N.C.; McPherson, Kan.; Austin, Texas; and Clayton, N.C., facilities, along with global engineering and program management. In 2012, he supported Hospira's efforts to produce and deliver more than half a billion units that were on the U.S. Food and Drug Administration (FDA) drug shortage list to help alleviate the industry-wide shortage for critical generic injectable drugs.

He joined Hospira from Johnson & Johnson, where he served as the vice president and global platform leader for solids, parenterals and vaccines. Mr. Stober has extensive experience managing transformational change in business-critical settings, as well as leading global and multi-company development projects, new product launches and large-scale organizational transformations. He has been in the pharmaceutical industry for nearly 25 years, having held significant leadership roles at Novartis Vaccines and Diagnostics, GlaxoSmithKline and Merck.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs